Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Bio-Thera Out-licenses EU Rights for Arthritis Biosimilar in $157 Million Deal

publication date: May 30, 2024

Bio-Thera Solutions, a Guangzhou biopharma focused on innovative and biosimilar drugs, sold European rights for a biosimilar to Germany’s STADA Arzneimittel in a $157.5 million agreement. The biosimilar is Golimumab (BAT2506), a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. BAT2506 is a proposed biosimilar to Janssen’s Simponi® (golimumab), which is approved to treat arthritis and other autoimmune disorders. In 2023, Bio-Thera completed a China Phase III trial of BAT2506 in psoriatic arthritis patients, but it hasn’t released the results. More details....

Stock Symbol: (SHA: 688177)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital